Injecting drug use: A vector for the introduction of new hepatitis C virus genotypes

World Journal of Gastroenterology

Volumn 21, Issue 38, 2015, Pages 10811-10823

  Ruta, Simona ^a   Cernescu, Costin ^a  

^a CAROL DAVILA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

Author keywords

Hepatitis C; Hepatitis C virus genotypes

Indexed keywords

ILLICIT DRUG; LEDIPASVIR; PEGINTERFERON ALPHA; RIBAVIRIN; SOFOSBUVIR; ANTIVIRUS AGENT;

ANTIVIRAL SUSCEPTIBILITY; ANTIVIRAL THERAPY; ARTICLE; CHRONIC HEPATITIS C; DEVELOPED COUNTRY; DEVELOPING COUNTRY; EPIDEMIC; GENOTYPE; GEOGRAPHIC DISTRIBUTION; GREECE; HEALTH CARE ACCESS; HEALTH CARE SYSTEM; HEALTH INSURANCE; HEPATITIS C; HEPATITIS C VIRUS; HEPATITIS C VIRUS GENOTYPE 1; HEPATITIS C VIRUS GENOTYPE 2; HEPATITIS C VIRUS GENOTYPE 4; HEPATITIS C VIRUS GENOTYPE 5; HEPATITIS C VIRUS GENOTYPE 6; HEPATITIS C VIRUS GENOTYPE 7; HEPATITIS C VIRUS SUBTYPE 3A; HIGH RISK POPULATION; HOMELESSNESS; HUMAN; INTRAVENOUS DRUG ABUSE; LIVER FIBROSIS; META ANALYSIS (TOPIC); NONHUMAN; PERSONALIZED MEDICINE; PHASE 3 CLINICAL TRIAL (TOPIC); PREVALENCE; REINFECTION; ROMANIA; UNEMPLOYMENT; VIREMIA; VIRUS RESISTANCE; VIRUS TRANSMISSION; AFRICA; ASIA; COMPLICATION; EUROPE; GENETICS; HEPACIVIRUS; NORTH AMERICA; PHYLOGEOGRAPHY; RISK FACTOR; SUBSTANCE ABUSE; TRANSMISSION; VIROLOGY;

AFRICA; ANTIVIRAL AGENTS; ASIA; EUROPE; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HUMANS; NORTH AMERICA; PHYLOGEOGRAPHY; PREVALENCE; RISK FACTORS; SEROEPIDEMIOLOGIC STUDIES; SUBSTANCE ABUSE, INTRAVENOUS;

EID: 84944080969     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v21.i38.10811     Document Type: Article

References (134)

1. Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, Abraham J, Adair T, Aggarwal R, Ahn SY, Alvarado M, Anderson HR, Anderson LM, Andrews KG, Atkinson C, Baddour LM, Barker-Collo S, Bartels DH, Bell ML, Benjamin EJ, Bennett D, Bhalla K, Bikbov B, Bin Abdulhak A, Birbeck G, Blyth F, Bolliger I, Boufous S, Bucello C, Burch M, Burney P, Carapetis J, Chen H, Chou D, Chugh SS, Coffeng LE, Colan SD, Colquhoun S, Colson KE, Condon J, Connor MD, Cooper LT, Corriere M, Cortinovis M, de Vaccaro KC, Couser W, Cowie BC, Criqui MH, Cross M, Dabhadkar KC, Dahodwala N, De Leo D, Degenhardt L, Delossantos A, Denenberg J, Des Jarlais DC, Dharmaratne SD, Dorsey ER, Driscoll T, Duber H, Ebel B, Erwin PJ, Espindola P, Ezzati M, Feigin V, Flaxman AD, Forouzanfar MH, Fowkes FG, Franklin R, Fransen M, Freeman MK, Gabriel SE, Gakidou E, Gaspari F, Gillum RF, Gonzalez-Medina D, Halasa YA, Haring D, Harrison JE, Havmoeller R, Hay RJ, Hoen B, Hotez PJ, Hoy D, Jacobsen KH, James SL, Jasrasaria R, Jayaraman S, Johns N, Karthikeyan G, Kassebaum N, Keren A, Khoo JP, Knowlton LM, Kobusingye O, Koranteng A, Krishnamurthi R, Lipnick M, Lipshultz SE, Ohno SL, Mabweijano J, MacIntyre MF, Mallinger L, March L, Marks GB, Marks R, Matsumori A, Matzopoulos R, Mayosi BM, McAnulty JH, McDermott MM, McGrath J, Mensah GA, Merriman TR, Michaud C, Miller M, Miller TR, Mock C, Mocumbi AO, Mokdad AA, Moran A, Mulholland K, Nair MN, Naldi L, Narayan KM, Nasseri K, Norman P, O'Donnell M, Omer SB, Ortblad K, Osborne R, Ozgediz D, Pahari B, Pandian JD, Rivero AP, Padilla RP, Perez-Ruiz F, Perico N, Phillips D, Pierce K, Pope CA, Porrini E, Pourmalek F, Raju M, Ranganathan D, Rehm JT, Rein DB, Remuzzi G, Rivara FP, Roberts T, De León FR, Rosenfeld LC, Rushton L, Sacco RL, Salomon JA, Sampson U, Sanman E, Schwebel DC, Segui-Gomez M, Shepard DS, Singh D, Singleton J, Sliwa K, Smith E, Steer A, Taylor JA, Thomas B, Tleyjeh IM, Towbin JA, Truelsen T, Undurraga EA, Venketasubramanian N, Vijayakumar L, Vos T, Wagner GR, Wang M, Wang W, Watt K, Weinstock MA, Weintraub R, Wilkinson JD, Woolf AD, Wulf S, Yeh PH, Yip P, Zabetian A, Zheng ZJ, Lopez AD, Murray CJ, AlMazroa MA, Memish ZA. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380: 2095-2128 [PMID: 23245604 DOI: 10.1016/S01406736(12)61728-0]
2. GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 2015; 385: 117-171 [PMID: 25530442 DOI: 10.1016/S0140-6736(14)61682-2]
3. Mohd Hanafah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of age-specifc antibody to HCV seroprevalence. Hepatology 2013; 57: 1333-1342 [PMID: 23172780 DOI: 10.1002/hep.26141]
4. Cooke GS, Lemoine M, Thursz M, Gore C, Swan T, Kamarulzaman A, DuCros P, Ford N. Viral hepatitis and the Global Burden of Disease: a need to regroup. J Viral Hepat 2013; 20: 600-601 [PMID: 23910643 DOI: 10.1111/jvh.12123]
5. Amin J, Law MG, Bartlett M, Kaldor JM, Dore GJ. Causes of death after diagnosis of hepatitis B or hepatitis C infection: a large community-based linkage study. Lancet 2006; 368: 938-945 [PMID: 16962883]
6. Quan PL, Firth C, Conte JM, Williams SH, Zambrana-Torrelio CM, Anthony SJ, Ellison JA, Gilbert AT, Kuzmin IV, Niezgoda M, Osinubi MO, Recuenco S, Markotter W, Breiman RF, Kalemba L, Malekani J, Lindblade KA, Rostal MK, Ojeda-Flores R, Suzan G, Davis LB, Blau DM, Ogunkoya AB, Alvarez Castillo DA, Moran D, Ngam S, Akaibe D, Agwanda B, Briese T, Epstein JH, Daszak P, Rupprecht CE, Holmes EC, Lipkin WI. Bats are a major natural reservoir for hepaciviruses and pegiviruses. Proc Natl Acad Sci USA 2013; 110: 8194-8199 [PMID: 23610427 DOI: 10.1073/pnas.1303037110]
7. Kapoor A, Simmonds P, Scheel TK, Hjelle B, Cullen JM, Burbelo PD, Chauhan LV, Duraisamy R, Sanchez Leon M, Jain K, Vandegrift KJ, Calisher CH, Rice CM, Lipkin WI. Identifcation of rodent homologs of hepatitis C virus and pegiviruses. MBio 2013; 4: e00216-e00213 [PMID: 23572554 DOI: 10.1128/mBio.00216-13]
8. Moradpour D, Penin F, Rice CM. Replication of hepatitis C virus. Nat Rev Microbiol 2007; 5: 453-463 [PMID: 17487147 DOI: 10.1038/nrmicro1645]
9. Smith DB, Bukh J, Kuiken C, Muerhoff AS, Rice CM, Stapleton JT, Simmonds P. Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource. Hepatology 2014; 59: 318-327 [PMID: 24115039 DOI: 10.1002/hep.26744]
10. Gower E, Estes C, Blach S, Razavi-Shearer K, Razavi H. Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol 2014; 61: S45-S57 [PMID: 25086286 DOI: 10.1016/j.jhep.2014.07.027]
11. Alter MJ. Epidemiology of hepatitis C virus infection. World J Gastroenterol 2007; 13: 2436-2441 [PMID: 17552026 DOI: 10.3748/wjg.v13.i17.2436]
12. United Nations Offce on Drugs and Crime. World Drug Report 2014. United Nations Publications, eISBN: 978-92-1-056752-7. Available from: URL: http://www.unodc.org/documents/wdr2014/World-Drug-Report-2014-web.pdf
13. Thomas LB, Foulis PR, Mastorides SM, Djilan YA, Skinner O, Borkowski AA. Hepatitis C genotype analysis: results in a large veteran population with review of the implications for clinical practice. Ann Clin Lab Sci 2012; 42: 355-362 [PMID: 23090730]
14. Esteban JI, Sauleda S, Quer J. The changing epidemiology of hepatitis C virus infection in Europe. J Hepatol 2008; 48: 148-162 [PMID: 18022726 DOI: 10.1016/j.jhep.2007.07.033]
15. European Centre for Disease Prevention and Control. Hepatitis B and C surveillance in Europe, 2012. Stockholm: ECDC, 2014 TQ-AU-14-001-EN-N Available from: URL: http://ecdc.europa.eu/en/hepatitis-b-c-surveillance-europe-2012-july-2014.pdf
16. Cornberg M, Razavi HA, Alberti A, Bernasconi E, Buti M, Cooper C, Dalgard O, Dillion JF, Flisiak R, Forns X, Frankova S, Goldis A, Goulis I, Halota W, Hunyady B, Lagging M, Largen A, Makara M, Manolakopoulos S, Marcellin P, Marinho RT, Pol S, Poynard T, Puoti M, Sagalova O, Sibbel S, Simon K, Wallace C, Young K, Yurdaydin C, Zuckerman E, Negro F, Zeuzem S. A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel. Liver Int 2011; 31 Suppl 2: 30-60 [PMID: 21651702 DOI: 10.1111/j.1478-3231.2011.02539.x]
17. Mathurin P. HCV burden in Europe and the possible impact of current treatment. Dig Liver Dis 2013; 45 Suppl 5: S314-S317 [PMID: 24091109 DOI: 10.1016/j.dld.2013.07.009]
18. McGarry LJ, Pawar VS, Panchmatia HR, Rubin JL, Davis GL, Younossi ZM, Capretta JC, O'Grady MJ, Weinstein MC. Economic model of a birth cohort screening program for hepatitis C virus. Hepatology 2012; 55: 1344-1355 [PMID: 22135116 DOI: 10.1002/hep.25510]
19. Kabiri M, Jazwinski AB, Roberts MS, Schaefer AJ, Chhatwal J. The changing burden of hepatitis C virus infection in the United States: model-based predictions. Ann Intern Med 2014; 161: 170-180 [PMID: 25089861 DOI: 10.7326/M14-0095]
20. Lewis H, Burke K, Begum S, Ushiro-Limb I, Foster G. What is the best method of case fnding for chronic viral Hepatitis in at-risk migrant communities? J Hepatology 2012; 56: S351 [DOI: 10.1016/S0168-8278(12)60915-5]
21. Litwin AH, Smith BD, Drainoni ML, McKee D, Gifford AL, Koppelman E, Christiansen CL, Weinbaum CM, Southern WN. Primary care-based interventions are associated with increases in hepatitis C virus testing for patients at risk. Dig Liver Dis 2012; 44: 497-503 [PMID: 22342471 DOI: 10.1016/j.dld.2011.12.014]
22. Hahné SJ, Veldhuijzen IK, Wiessing L, Lim TA, Salminen M, Laar Mv. Infection with hepatitis B and C virus in Europe: a systematic review of prevalence and cost-effectiveness of screening. BMC Infect Dis 2013; 13: 181 [PMID: 23597411 DOI: 10.1186/1471-2334-13-181]
23. Degenhardt L, Whiteford HA, Ferrari AJ, Baxter AJ, Charlson FJ, Hall WD, Freedman G, Burstein R, Johns N, Engell RE, Flaxman A, Murray CJ, Vos T. Global burden of disease attributable to illicit drug use and dependence: fndings from the Global Burden of Disease Study 2010. Lancet 2013; 382: 1564-1574 [PMID: 23993281 DOI: 10.1016/S0140-6736(13)61530-5]
24. World Health Organization. A strategy to halt and reverse the HIV epidemic among people who inject drugs in Asia and the Pacific: 2010-2015, WHO Library Cataloguing 2015. Available from: URL: http://iris.wpro.who.int/handle/10665.1/5506
25. Nelson PK, Mathers BM, Cowie B, Hagan H, Des Jarlais D, Horyniak D, Degenhardt L. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. Lancet 2011; 378: 571-583 [PMID: 21802134 DOI: 10.1016/S0140-6736(11)61097-0]
26. Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 2006; 144: 705-714 [PMID: 16702586 DOI: 10.7326/0003-4819-144-10-2006 05160-00004]
27. Page K, Morris MD, Hahn JA, Maher L, Prins M. Injection drug use and hepatitis C virus infection in young adult injectors: using evidence to inform comprehensive prevention. Clin Infect Dis 2013; 57 Suppl 2: S32-S38 [PMID: 23884063 DOI: 10.1093/cid/cit300]
28. Tseng FC, O'Brien TR, Zhang M, Kral AH, Ortiz-Conde BA, Lorvick J, Busch MP, Edlin BR. Seroprevalence of hepatitis C virus and hepatitis B virus among San Francisco injection drug users, 1998 to 2000. Hepatology 2007; 46: 666-671 [PMID: 17657818 DOI: 10.1002/hep.21765]
29. Ly KN, Xing J, Klevens RM, Jiles RB, Ward JW, Holmberg SD. The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007. Ann Intern Med 2012; 156: 271-278 [PMID: 22351712 DOI: 10.7326/0003-4819-156-4-20120 2210-00004]
30. Mühlberger N, Schwarzer R, Lettmeier B, Sroczynski G, Zeuzem S, Siebert U. HCV-related burden of disease in Europe: a systematic assessment of incidence, prevalence, morbidity, and mortality. BMC Public Health 2009; 9: 34 [PMID: 19161623 DOI: 10.1186/1471-2458-9-34]
31. Sarna A, Panda S. HCV in people who inject drugs: a neglected epidemic. Lancet Infect Dis 2015; 15: 4-5 [PMID: 25486850 DOI: 10.1016/S1473-3099(14)71054-0]
32. Hope VD, Eramova I, Capurro D, Donoghoe MC. Prevalence and estimation of hepatitis B and C infections in the WHO European Region: a review of data focusing on the countries outside the European Union and the European Free Trade Association. Epidemiol Infect 2014; 142: 270-286 [PMID: 23714072 DOI: 10.1017/S0950268813000940]
33. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). European Drug Report. Trends and developments 2014. Luxembourg: Publications Office of the European Union, 2014. Available from: URL: http://www.ab.gov.tr/files/ardb/evt/european-drug-report-2014.pdf
34. Wiessing L, Ferri M, Grady B, Kantzanou M, Sperle I, Cullen KJ, Hatzakis A, Prins M, Vickerman P, Lazarus J V, Hope VD, Matheï C. Hepatitis C virus infection epidemiology among people who inject drugs in Europe: a systematic review of data for scaling up treatment and prevention. PLoS One 2014; 9: e103345 [PMID: 25068274 DOI: 10.1371/journal.pone.0103345]
35. Pilon R, Leonard L, Kim J, Vallee D, De Rubeis E, Jolly AM, Wylie J, Pelude L, Sandstrom P. Transmission patterns of HIV and hepatitis C virus among networks of people who inject drugs. PLoS One 2011; 6: e22245 [PMID: 21799802 DOI: 10.1371/journal. pone.0022245]
36. Vickerman P, Martin NK, Roy A, Beattie T, Jarlais DD, Strathdee S, Wiessing L, Hickman M. Is the HCV-HIV co-infection prevalence amongst injecting drug users a marker for the level of sexual and injection related HIV transmission? Drug Alcohol Depend 2013; 132: 172-181 [PMID: 23453261 DOI: 10.1016/j.dru galcdep.2013.01.020]
37. Wiessing L, Likatavicius G, Hedrich D, Guarita B, van de Laar MJ, Vicente J. Trends in HIV and hepatitis C virus infections among injecting drug users in Europe, 2005 to 2010. Euro Surveill 2011; 16: pii 20031 [PMID: 22172300]
38. Lidman C, Norden L, Kåberg M, Käll K, Franck J, Aleman S, Birk M. Hepatitis C infection among injection drug users in Stockholm Sweden: prevalence and gender. Scand J Infect Dis 2009; 41: 679-684 [PMID: 19521924 DOI: 10.1080/00365540903062143]
39. García-Fulgueiras A, García-Pina R, Morant C, de Larrea-Baz NF, Alvarez E. Burden of disease related to hepatitis C and hepatitis B in Spain: a methodological challenge of an unfolding health problem. J Viral Hepat 2011; 18: e453-e460 [PMID: 21914063 DOI: 10.1111/j.1365-2893.2011.01467.x]
40. Vermehren J, Schlosser B, Domke D, Elanjimattom S, Müller C, Hintereder G, Hensel-Wiegel K, Tauber R, Berger A, Haas N, Walcher F, Möckel M, Lehmann R, Zeuzem S, Sarrazin C, Berg T. High prevalence of anti-HCV antibodies in two metropolitan emergency departments in Germany: a prospective screening analysis of 28, 809 patients. PLoS One 2012; 7: e41206 [PMID: 22848445 DOI: 10.1371/journal.pone.0041206]
41. Flisiak R, Halota W, Tomasiewicz K, Kostrzewska K, Razavi HA, Gower EE. Forecasting the disease burden of chronic hepatitis C virus in Poland. Eur J Gastroenterol Hepatol 2015; 27: 70-76 [PMID: 25426979 DOI: 10.1097/MEG.0000000000000237]
42. Blachier M, Leleu H, Peck-Radosavljevic M, Valla DC, Roudot-Thoraval F. The burden of liver disease in Europe: a review of available epidemiological data. J Hepatol 2013; 58: 593-608 [PMID: 23419824 DOI: 10.1016/j.jhep.2012.12.005]
43. Messina JP, Humphreys I, Flaxman A, Brown A, Cooke GS, Pybus OG, Barnes E. Global distribution and prevalence of hepatitis C virus genotypes. Hepatology 2015; 61: 77-87 [PMID: 25069599 DOI: 10.1002/hep.27259]
44. Mao XR, Zhang LT, Chen H, Xiao P, Zhang YC. Correlation between the genetic variations in interleukin 28B and chronic hepatitis C virus genotypes in the Chinese population. Mol Med Rep 2014; 10: 1037-1045 [PMID: 24840747 DOI: 10.3892/mmr.2014.2242]
45. Li C, Barnes E, Newton PN, Fu Y, Vongsouvath M, Klenerman P, Okamoto H, Abe K, Pybus OG, Lu L. An expanded taxonomy of hepatitis C virus genotype 6: Characterization of 22 new full-length viral genomes. Virology 2015; 476: 355-363 [PMID: 25589238 DOI: 10.1016/j.virol.2014.12.025]
46. Ray SC, Arthur RR, Carella A, Bukh J, Thomas DL. Genetic epidemiology of hepatitis C virus throughout egypt. J Infect Dis 2000; 182: 698-707 [PMID: 10950762 DOI: 10.1086/315786]
47. Ramia S, Melhem NM, Kreidieh K. Hepatitis C virus infection in the Middle East and North Africa "MENA" region: injecting drug users (IDUs) is an under-investigated population. Infection 2012; 40: 1-10 [PMID: 22237470 DOI: 10.1007/s15010-011-0236-z]
48. Papastergiou V, Karatapanis S. Current status and emerging challenges in the treatment of hepatitis C virus genotypes 4 to 6. World J Clin Cases 2015; 3: 210-220 [PMID: 25789294 DOI: 10.12998/wjcc.v3.i3.210]
49. Gededzha MP, Selabe SG, Blackard JT, Kyaw T, Mphahlele MJ. Near full-length genome analysis of HCV genotype 5 strains from South Africa. Infect Genet Evol 2014; 21: 118-123 [PMID: 24220189 DOI: 10.1016/j.meegid.2013.10.022]
50. Ohno O, Mizokami M, Wu RR, Saleh MG, Ohba K, Orito E, Mukaide M, Williams R, Lau JY. New hepatitis C virus (HCV) genotyping system that allows for identifcation of HCV genotypes 1a, 1b, 2a, 2b, 3a, 3b, 4, 5a, and 6a. J Clin Microbiol 1997; 35: 201-207 [PMID: 8968908]
51. Villar LM, Ó KM, Scalioni LP, Cruz HM, Portilho MM, Mendonça AC, Miguel JC, Figueiredo AS, Almeida AJ, Lampe E. Prevalence of hepatitis B and C virus infections among military personnel. Braz J Infect Dis 2015; 19: 285-290 [PMID: 25769737 DOI: 10.1016/j.bjid.2015.02.002]
52. Bruggmann P, Berg T, Øvrehus AL, Moreno C, Brandão Mello CE, Roudot-Thoraval F, Marinho RT, Sherman M, Ryder SD, Sperl J, Akarca U, Balik I, Bihl F, Bilodeau M, Blasco AJ, Buti M, Calinas F, Calleja JL, Cheinquer H, Christensen PB, Clausen M, Coelho HS, Cornberg M, Cramp ME, Dore GJ, Doss W, Duberg AS, El-Sayed MH, Ergör G, Esmat G, Estes C, Falconer K, Félix J, Ferraz ML, Ferreira PR, Frankova S, García-Samaniego J, Gerstoft J, Giria JA, Gonçales FL, Gower E, Gschwantler M, Guimarães Pessôa M, Hézode C, Hofer H, Husa P, Idilman R, Kåberg M, Kaita KD, Kautz A, Kaymakoglu S, Krajden M, Krarup H, Laleman W, Lavanchy D, Lázaro P, Marotta P, Mauss S, Mendes Correa MC, Müllhaupt B, Myers RP, Negro F, Nemecek V, Örmeci N, Parkes J, Peltekian KM, Ramji A, Razavi H, Reis N, Roberts SK, Rosenberg WM, Sarmento-Castro R, Sarrazin C, Semela D, Shiha GE, Sievert W, Stärkel P, Stauber RE, Thompson AJ, Urbanek P, van Thiel I, Van Vlierberghe H, Vandijck D, Vogel W, Waked I, Wedemeyer H, Weis N, Wiegand J, Yosry A, Zekry A, Van Damme P, Aleman S, Hindman SJ. Historical epidemiology of hepatitis C virus (HCV) in selected countries. J Viral Hepat 2014; 21 Suppl 1: 5-33 [PMID: 24713004 DOI: 10.1111/jvh.12247]
53. Payan C, Roudot-Thoraval F, Marcellin P, Bled N, Duverlie G, Fouchard-Hubert I, Trimoulet P, Couzigou P, Cointe D, Chaput C, Henquell C, Abergel A, Pawlotsky JM, Hezode C, Coudé M, Blanchi A, Alain S, Loustaud-Ratti V, Chevallier P, Trepo C, Gerolami V, Portal I, Halfon P, Bourlière M, Bogard M, Plouvier E, Laffont C, Agius G, Silvain C, Brodard V, Thiefn G, Buffet-Janvresse C, Riachi G, Grattard F, Bourlet T, Stoll-Keller F, Doffoel M, Izopet J, Barange K, Martinot-Peignoux M, Branger M, Rosenberg A, Sogni P, Chaix ML, Pol S, Thibault V, Opolon P, Charrois A, Serfaty L, Fouqueray B, Grange JD, Lefrère JJ, Lunel-Fabiani F. Changing of hepatitis C virus genotype patterns in France at the beginning of the third millenium: The GEMHEP GenoCII Study. J Viral Hepat 2005; 12: 405-413 [PMID: 15985012 DOI: 10.1111/j.1365-2893.2005.00605.x]
54. Cifuentes C, Mancebo-Hernández M, Pérez-Navarro E, Recio E, Monje-Agudo P, Valiente A, Pineda JA. [Prevalence and genotype distribution changes in hepatitis C virus co-infection among human immunodefciency virus-infected patients]. Enferm Infecc Microbiol Clin 2015; 33: 110-112 [PMID: 25510595 DOI: 10.1016/j.eimc.2014.05.010]
55. Candotti D, Temple J, Sarkodie F, Allain JP. Frequent recovery and broad genotype 2 diversity characterize hepatitis C virus infection in Ghana, West Africa. J Virol 2003; 77: 7914-7923 [PMID: 12829831 DOI: 10.1128/JVI.77.14.7914-7923.2003]
56. Osella AR, Misciagna G, Guerra V, Elba S, Buongiorno G, Cavallini A, Di Leo A, Sonzogni L, Mondelli MU, Silini EM. Hepatitis C virus genotypes and risk of cirrhosis in southern Italy. Clin Infect Dis 2001; 33: 70-75 [PMID: 11389497 DOI: 10.1086/320887]
57. Ansaldi F, Bruzzone B, Salmaso S, Rota MC, Durando P, Gasparini R, Icardi G. Different seroprevalence and molecular epidemiology patterns of hepatitis C virus infection in Italy. J Med Virol 2005; 76: 327-332 [PMID: 15902713 DOI: 10.1002/jmv.20376]
58. Yin W, Huang C, Qiu F, Liu L, Wang F, Zhou J, Zhang Y, Bi S. Risk factors of hepatitis C virus transmission and genotype distribution in former blood donors from Chinese rural area. BMC Public Health 2015; 15: 184 [PMID: 25884321 DOI: 10.1186/s12889-015-1535-6]
59. Morice Y, Cantaloube JF, Beaucourt S, Barbotte L, De Gendt S, Goncales FL, Butterworth L, Cooksley G, Gish RG, Beaugrand M, Fay F, Fay O, Gonzalez JE, Martins RM, Dhumeaux D, Vanderborght B, Stuyver L, Sablon E, de Lamballerie X, Pawlotsky JM. Molecular epidemiology of hepatitis C virus subtype 3a in injecting drug users. J Med Virol 2006; 78: 1296-1303 [PMID: 16927280 DOI: 10.1002/jmv.20692]
60. Stroffolini T, Fiumeb A, Fataleb G, Regnib F, Ciccozzia M, Marzolinia A, Mele A. Hepatitis C virus among intravenous drug users in Italy. Hepatology Research 1997; 9: 20-27 [DOI: 10.1016/S1386-6346(97)00084-3]
61. Calado RA, Rocha MR, Parreira R, Piedade J, Venenno T, Esteves A. Hepatitis C virus subtypes circulating among intravenous drug users in Lisbon, Portugal. J Med Virol 2011; 83: 608-615 [PMID: 21328374 DOI: 10.1002/jmv.21955]
62. Sereno S, Perinelli P, Laghi V. Changes in the prevalence of hepatitis C virus genotype among Italian injection drug users-relation to period of injection started. J Clin Virol 2009; 45: 354-357 [PMID: 19497783 DOI: 10.1016/j.jcv.2009.04.022]
63. Mohamoud YA, Mumtaz GR, Riome S, Miller D, Abu-Raddad LJ. The epidemiology of hepatitis C virus in Egypt: a systematic review and data synthesis. BMC Infect Dis 2013; 13: 288 [PMID: 23799878 DOI: 10.1186/1471-2334-13-288]
64. Kamal SM, Nasser IA. Hepatitis C genotype 4: What we know and what we don't yet know. Hepatology 2008; 47: 1371-1383 [PMID: 18240152 DOI: 10.1002/hep.22127]
65. Xu LZ, Larzul D, Delaporte E, Bréchot C, Kremsdorf D. Hepatitis C virus genotype 4 is highly prevalent in central Africa (Gabon). J Gen Virol 1994; 75 (Pt 9): 2393-2398 [PMID: 8077938 DOI: 10.1099/0022-1317-75-9-2393]
66. Iles JC, Raghwani J, Harrison GL, Pepin J, Djoko CF, Tamoufe U, LeBreton M, Schneider BS, Fair JN, Tshala FM, Kayembe PK, Muyembe JJ, Edidi-Basepeo S, Wolfe ND, Simmonds P, Klenerman P, Pybus OG. Phylogeography and epidemic history of hepatitis C virus genotype 4 in Africa. Virology 2014; 464-465: 233-243 [PMID: 25105489 DOI: 10.1016/j.virol.2014.07.006]
67. Thong VD, Akkarathamrongsin S, Poovorawan K, Tangkijvanich P, Poovorawan Y. Hepatitis C virus genotype 6: virology, epidemiology, genetic variation and clinical implication. World J Gastroenterol 2014; 20: 2927-2940 [PMID: 24659883 DOI: 10.3748/wjg.v20.i11.2927]
68. Murphy DG, Willems B, Deschênes M, Hilzenrat N, Mousseau R, Sabbah S. Use of sequence analysis of the NS5B region for routine genotyping of hepatitis C virus with reference to C/E1 and 5' untranslated region sequences. J Clin Microbiol 2007; 45: 1102-1112 [PMID: 17287328 DOI: 10.1128/jcm.02366-06]
69. Karatapanis S, Tsoplou P, Papastergiou V, Vasiageorgi A, Stampori M, Saitis I, Tsitsopoulos E, Lisgos P, Skorda L, Ketikoglou I, Goulis I. Hepatitis C virus genotyping in Greece: unexpected high prevalence of genotype 5a in a Greek island. J Med Virol 2012; 84: 223-228 [PMID: 22170541 DOI: 10.1002/jmv.22249]
70. Paintsil E, Verevochkin S V, Dukhovlinova E, Niccolai L, Barbour R, White E, Toussova OV, Alexander L, Kozlov AP, Heimer R. Hepatitis C virus infection among drug injectors in St Petersburg, Russia: social and molecular epidemiology of an endemic infection. Addiction 2009; 104: 1881-1890 [PMID: 19712125 DOI: 10.1111/j.1360-0443.2009.02687.x]
71. Tallo T, Norder H, Tefanova V, Krispin T, Schmidt J, Ilmoja M, Orgulas K, Pruunsild K, Priimägi L, Magnius LO. Genetic characterization of hepatitis C virus strains in Estonia: fuctuations in the predominating subtype with time. J Med Virol 2007; 79: 374-382 [PMID: 17311333 DOI: 10.1002/jmv.20828]
72. Ciccozzi M, Zehender G, Cento V, Lo Presti A, Teoharov P, Pavlov I, Bogdanova V, Perno CF, Ciotti M. Molecular analysis of hepatitis C virus infection in Bulgarian injecting drug users. J Med Virol 2011; 83: 1565-1570 [PMID: 21739447 DOI: 10.1002/jmv.22154]
73. Svirtlih N, Delic D, Simonovic J, Jevtovic D, Dokic L, Gvozdenovic E, Boricic I, Terzic D, Pavic S, Neskovic G, Zerjav S, Urban V. Hepatitis C virus genotypes in Serbia and Montenegro: the prevalence and clinical significance. World J Gastroenterol 2007; 13: 355-360 [PMID: 17230602 DOI: 10.3748/wjg.v13. i3.355]
74. Chlabicz S, Flisiak R, Kowalczuk O, Grzeszczuk A, Pytel-Krolczuk B, Prokopowicz D, Chyczewski L. Changing HCV genotypes distribution in Poland-relation to source and time of infection. J Clin Virol 2008; 42: 156-159 [PMID: 18353714 DOI: 10.1016/j.jcv.2008.02.001]
75. Sultana C, Vagu C, Temereanca A, Grancea C, Slobozeanu J, Ruta S. Hepatitis C Virus Genotypes in Injecting Drug Users from Romania. Cent Eur J Med 2011; 6: 672-678 [PMID: 23585824 DOI: 10.2478/s11536-011-0073-6]
76. May S, Ngui SL, Collins S, Lattimore S, Ramsay M, Tedder RS, Ijaz S. Molecular epidemiology of newly acquired hepatitis C infections in England 2008-2011: genotype, phylogeny and mutation analysis. J Clin Virol 2015; 64: 6-11 [PMID: 25728071 DOI: 10.1016/j.jcv.2014.12.01410.1016/j.jcv.2014.12.014]
77. Katsoulidou A, Sypsa V, Tassopoulos NC, Boletis J, Karafoulidou A, Ketikoglou I, Tsantoulas D, Vafadi I, Hatzis G, Skoutelis A, Akriviadis E, Vasiliadis T, Kitis G, Magiorkinis G, Hatzakis A. Molecular epidemiology of hepatitis C virus (HCV) in Greece: temporal trends in HCV genotype-specifc incidence and molecular characterization of genotype 4 isolates. J Viral Hepat 2006; 13: 19-27 [PMID: 16364078 DOI: 10.1111/j.1365-2893.2005.00649.x]
78. Matera G, Lamberti A, Quirino A, Focà D, Giancotti A, Barreca GS, Guadagnino V, Liberto MC. Changes in the prevalence of hepatitis C virus (HCV) genotype 4 in Calabria, Southern Italy. Diagn Microbiol Infect Dis 2002; 42: 169-173 [PMID: 11929687 DOI: 10.1016/S0732-8893(01)00350-9]
79. Liberto MC, Marascio N, Zicca E, Matera G. Epidemiological features and specifcities of HCV infection: a hospital-based cohort study in a university medical center of Calabria region. BMC Infect Dis 2012; 12 Suppl 2: S4 [PMID: 23173638 DOI: 10.1186/1471-2 334-12-S2-S4]
80. Sánchez-Quijano A, Abad MA, Torronteras R, Rey C, Pineda JA, Leal M, Macias J, Lissen E. Unexpected high prevalence of hepatitis C virus genotype 4 in Southern Spain. J Hepatol 1997; 27: 25-29 [PMID: 9252069 DOI: 10.1016/S0168-8278(97)80275-9]
81. de Bruijne J, Schinkel J, Prins M, Koekkoek SM, Aronson SJ, van Ballegooijen MW, Reesink HW, Molenkamp R, van de Laar TJ. Emergence of hepatitis C virus genotype 4: phylogenetic analysis reveals three distinct epidemiological profiles. J Clin Microbiol 2009; 47: 3832-3838 [PMID: 19794040 DOI: 10.1128/JCM.01146-09]
82. Cacoub P, Dabis F, Costagliola D, Almeida K, Lert F, Piroth L, Semaille C. Burden of HIV and hepatitis C co-infection: the changing epidemiology of hepatitis C in HIV-infected patients in France. Liver Int 2015; 35: 65-70 [PMID: 25040895 DOI: 10.1111/liv.12639]
83. Cebolla B, Björnberg A, editors. Health Consumer Powerhouse: Euro Hepatitis Index Report. 2012. Available from: URL: http://www.healthpowerhouse.com
84. Pharris A, Wiessing L, Sfetcu O, Hedrich D, Botescu A, Fotiou A, Nikolopoulos GK, Malliori M, Salminen M, Suk JE, Griffths P, van de Laar MJ. Human immunodefciency virus in injecting drug users in Europe following a reported increase of cases in Greece and Romania, 2011. Euro Surveill 2011; 16: pii 20032 [PMID: 22172301]
85. Paraskevis D, Nikolopoulos G, Tsiara C, Paraskeva D, Antoniadou A, Lazanas M, Gargalianos P, Psychogiou M, Malliori M, Kremastinou J, Hatzakis A. HIV-1 outbreak among injecting drug users in Greece, 2011: a preliminary report. Euro Surveill 2011; 16: pii 19962 [PMID: 21924120]
86. Oprea C, Ceausu E, Ruta S. Ongoing outbreak of multiple blood-borne infections in injecting drug users in Romania. Public Health 2013; 127: 1048-1050 [PMID: 24239282 DOI: 10.1016/j.puhe.2013.08.018]
87. European Commision. Eurostat Yearbook, 2014. Available from: URL: http://ec.europa.eu/eurostat
88. Sypsa V, Paraskevis D, Malliori M, Nikolopoulos GK, Panopoulos A, Kantzanou M, Katsoulidou A, Psichogiou M, Fotiou A, Pharris A, Van De Laar M, Wiessing L, Jarlais DD, Friedman SR, Hatzakis A. Homelessness and Other Risk Factors for HIV Infection in the Current Outbreak Among Injection Drug Users in Athens, Greece. Am J Public Health 2015; 105: 196-204 [PMID: 24524508 DOI: 10.2105/AJPH.2013.301656]
89. Sultana C, Oprisan G, Szmal C, Vagu C, Temereanca A, Dinu S, Teleman MD, Ruta S. Molecular epidemiology of hepatitis C virus strains from Romania. J Gastrointestin Liver Dis 2011; 20: 261-266 [PMID: 21961093]
90. Niculescu I, Paraschiv S, Paraskevis D, Abagiu A, Batan I, Banica L, Otelea D. Recent HIV-1 Outbreak Among Intravenous Drug Users in Romania: Evidence for Cocirculation of CRF14-BG and Subtype F1 Strains. AIDS Res Hum Retroviruses 2015; 31: 488-495 [PMID: 25369079 DOI: 10.1089/aid.2014.0189]
91. Gigi E, Sinakos E, Sykja A, Androulakis G, Tanis C, Stayridou V, Tsirogianni E, Zouridakis K, Bellou AL, Orfanou E, Raptopoulou-Gigi M. Epidemiology, clinical data, and treatment of viral hepatitis in a large cohort of intravenous drug users. J Addict Med 2013; 7: 52-57 [PMID: 23340710 DOI: 10.1097/ADM.0b013e318279756f]
92. Paraskevis D, Nikolopoulos G, Fotiou A, Tsiara C, Paraskeva D, Sypsa V, Lazanas M, Gargalianos P, Psichogiou M, Skoutelis A, Wiessing L, Friedman SR, Jarlais DC, Terzidou M, Kremastinou J, Malliori M, Hatzakis A. Economic recession and emergence of an HIV-1 outbreak among drug injectors in Athens metropolitan area: a longitudinal study. PLoS One 2013; 8: e78941 [PMID: 24265730 DOI: 10.1371/journal.pone.0078941]
93. International Organization for Migration. The World Migration Report 2013: Migrant Well-being and Development-the 7th report in IOM's World Migration Report series, 2013, Geneva. Available from: URL: http://www.iom.int
94. Marascio N, Liberto M, Barreca G, Zicca E, Quirino A, Lamberti A, Bianco G, Matera G, Surace L, Berardelli G, Surace L, De Maria V, Giancotti F, Leone R, Villella V, Nisticò S, Borelli A, Caruso V, Calderazzo M, Griffo G, Masciari R, Minchella P, Cosco L, Laganà C, Oliva A Foti G, Fiorillo M, Bocchiaro G, Surace P, Ciccaglione A, Ciccozzi M, Cesario F, Torti C, Focà A. Update on epidemiology of HCV in Italy: focus on the Calabria Region. BMC Infect Dis 2014; 14 Suppl 5: S2 [PMID: 25236184 DOI: 10.1186/1 471-2334-14-S5-S2]
95. Zehender G, Sorrentino C, Lai A, Ebranati E, Gabanelli E, Lo Presti A Vujoevic D, Lauevic D, Terzic D, Shkjezi R, Bino S, Vratnica Z, Mugosa B, Galli M, Ciccozzi M. Reconstruction of the evolutionary dynamics of hepatitis C virus subtypes in Montenegro and the Balkan region. Infect Genet Evol 2013; 17: 223-230 [PMID: 23603418 DOI: 10.1016/j.meegid.2013.04.003]
96. Di Lello FA, Neukam K, Parra-Sanchez M, Plaza Z, Soriano V, Cifuentes C, Mira JA, Poveda E, Pineda JA. Hepatitis C virus genotype 4 in Southern and Central Spain does not originate from recent foreign migration waves. J Med Virol 2013; 85: 1734-1740 [PMID: 23861220 DOI: 10.1002/jmv.23657]
97. Ciccozzi M, Equestre M, Costantino A, Marascio N, Quirino A, Lo Presti A, Cella E, Bruni R, Liberto MC, Focà A, Pisani G, Zehender G, Ciccaglione AR. Hepatitis C virus genotype 4d in Southern Italy: reconstruction of its origin and spread by a phylodynamic analysis. J Med Virol 2012; 84: 1613-1619 [PMID: 22930510 DOI: 10.1002/jmv.23384]
98. Sacks-Davis R, Daraganova G, Aitken C, Higgs P, Tracy L, Bowden S, Jenkinson R, Rolls D, Pattison P, Robins G, Grebely J, Barry A, Hellard M. Hepatitis C virus phylogenetic clustering is associated with the social-injecting network in a cohort of people who inject drugs. PLoS One 2012; 7: e47335 [PMID: 23110068 DOI: 10.1371/journal. pone. 0047335]
99. Jacka B, Applegate T, Krajden M, Olmstead A, Harrigan PR, Marshall BD, DeBeck K, Milloy MJ, Lamoury F, Pybus OG, Lima VD, Magiorkinis G, Montoya V, Montaner J, Joy J, Woods C, Dobrer S, Dore GJ, Poon AF, Grebely J. Phylogenetic clustering of hepatitis C virus among people who inject drugs in Vancouver, Canada. Hepatology 2014; 60: 1571-1580 [PMID: 25042607 DOI: 10.1002/hep.27310]
100. Lim SG. Chronic hepatitis C genotype 1 treatment roadmap for resource constrained settings. World J Gastroenterol 2015; 21: 1972-1981 [PMID: 25684966 DOI: 10.3748/wjg.v21.i6.1972]
101. Abenavoli L, Masarone M, Peta V, Milic N, Kobyliak N, Rouabhia S, Persico M. Insulin resistance and liver steatosis in chronic hepatitis C infection genotype 3. World J Gastroenterol 2014; 20: 15233-15240 [PMID: 25386071 DOI: 10.3748/wjg.v20.i41.15233]
102. Quer J, Gregori J, Rodríguez-Frias F, Buti M, Madejon A, Perez-del-Pulgar S, Garcia-Cehic D, Casillas R, Blasi M, Homs M, Tabernero D, Alvarez-Tejado M, Muñoz JM, Cubero M, Caballero A, del Campo JA, Domingo E, Belmonte I, Nieto L, Lens S, Muñoz-de-Rueda P, Sanz-Cameno P, Sauleda S, Bes M, Gomez J, Briones C, Perales C, Sheldon J, Castells L, Viladomiu L, Salmeron J, Ruiz-Extremera A, Quiles-Pérez R, Moreno-Otero R, López-Rodríguez R, Allende H, Romero-Gómez M, Guardia J, Esteban R, Garcia-Samaniego J, Forns X, Esteban JI. High-resolution hepatitis C virus subtyping using NS5B deep sequencing and phylogeny, an alternative to current methods. J Clin Microbiol 2015; 53: 219-226 [PMID: 25378574 DOI: 10.1128/JCM.02093-14]
103. World Health Organization (WHO). Guidelines for the screening, care and treatment of persons with hepatitis C infection. WHO Library Cataloguing-in-Publication 2014. Available from URL: http://www.who.int/hepatitis/hepatitis-c-guidelines/
104. American Association for the Study of Liver Diseases (AASLD) and Infectious Diseases Society of America. Recommendations for testing, managing, and treating hepatitis C. 2014. Available from: URL: http://www.hcvguidelines.org/full-report-view
105. European Association for Study of Liver. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol 2014; 60: 392-420 [PMID: 24331294 DOI: 10.1016/j.jhep.2013.11.003]
106. Kohli A, Shaffer A, Sherman A, Kottilil S. Treatment of hepatitis C: a systematic review. JAMA 2014; 312: 631-640 [PMID: 25117132 DOI: 10.1001/jama.2014.7085]
107. Kowdley KV, Gordon SC, Reddy KR, Rossaro L, Bernstein DE, Lawitz E, Shiffman ML, Schiff E, Ghalib R, Ryan M, Rustgi V, Chojkier M, Herring R, Di Bisceglie AM, Pockros PJ, Subramanian GM, An D, Svarovskaia E, Hyland RH, Pang PS, Symonds WT, McHutchison JG, Muir AJ, Pound D, Fried MW. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med 2014; 370: 1879-1888 [PMID: 24720702 DOI: 10.1056/NEJMoa1402355]
108. Jacobson IM, Gordon SC, Kowdley KV, Yoshida EM, Rodriguez-Torres M, Sulkowski MS, Shiffman ML, Lawitz E, Everson G, Bennett M, Schiff E, Al-Assi MT, Subramanian GM, An D, Lin M, McNally J, Brainard D, Symonds WT, McHutchison JG, Patel K, Feld J, Pianko S, Nelson DR. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med 2013; 368: 1867-1877 [PMID: 23607593 DOI: 10.1056/NEJMoa1214854]
109. Zeuzem S, Dusheiko GM, Salupere R, Mangia A, Flisiak R, Hyland RH, Illeperuma A, Svarovskaia E, Brainard DM, Symonds WT, Subramanian GM, McHutchison JG, Weiland O, Reesink HW, Ferenci P, Hézode C, Esteban R. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Engl J Med 2014; 370: 1993-2001 [PMID: 24795201 DOI: 10.1056/NEJMoa1316145]
110. Ferenci P. Treatment of hepatitis C in diffcult-to-treat patients. Nat Rev Gastroenterol Hepatol 2015; 12: 284-292 [PMID: 25895822 DOI: 10.1038/nrgastro.2015.53]
111. Koff RS. Review article: the effcacy and safety of sofosbuvir, a novel, oral nucleotide NS5B polymerase inhibitor, in the treatment of chronic hepatitis C virus infection. Aliment Pharmacol Ther 2014; 39: 478-487 [PMID: 24387618 DOI: 10.1111/apt.12601]
112. Lawitz E, Poordad F, Brainard DM, Hyland RH, An D, Dvory-Sobol H, Symonds WT, McHutchison JG, Membreno FE. Sofosbuvir with peginterferon-ribavirin for 12 weeks in previously treated patients with hepatitis C genotype 2 or 3 and cirrhosis. Hepatology 2015; 61: 769-775 [PMID: 25322962 DOI: 10.1002/hep.27567]
113. Akkarathamrongsin S, Payungporn S, Thong VD, Poovorawan K, Prapunwattana P, Poovorawan Y, Tangkijvanich P. Early viral kinetics during hepatitis C virus genotype 6 treatment according to IL28B polymorphisms. World J Gastroenterol 2014; 20: 10599-10605 [PMID: 25132781 DOI: 10.3748/wjg.v20.i30.10599]
114. Sullivan JC, De Meyer S, Bartels DJ, Dierynck I, Zhang EZ, Spanks J, Tigges AM, Ghys A, Dorrian J, Adda N, Martin EC, Beumont M, Jacobson IM, Sherman KE, Zeuzem S, Picchio G, Kieffer TL. Evolution of treatment-emergent resistant variants in telaprevir phase 3 clinical trials. Clin Infect Dis 2013; 57: 221-229 [PMID: 23575197 DOI: 10.1093/cid/cit226]
115. Ogert RA, Howe JA, Vierling JM, Kwo PY, Lawitz EJ, McCone J, Schiff ER, Pound D, Davis MN, Gordon SC, Ravendhran N, Rossaro L, Jacobson IM, Ralston R, Chaudhri E, Qiu P, Pedicone LD, Brass CA, Albrecht JK, Barnard RJ, Hazuda DJ, Howe AY. Resistance-associated amino acid variants associated with boceprevir plus pegylated interferon-α2b and ribavirin in patients with chronic hepatitis C in the SPRINT-1 trial. Antivir Ther 2013; 18: 387-397 [PMID: 23406826 DOI: 10.3851/IMP2549]
116. Barnard RJ, Howe JA, Ogert RA, Zeuzem S, Poordad F, Gordon SC, Ralston R, Tong X, Sniukiene V, Strizki J, Ryan D, Long J, Qiu P, Brass CA, Albrecht J, Burroughs M, Vuocolo S, Hazuda DJ. Analysis of boceprevir resistance associated amino acid variants (RAVs) in two phase 3 boceprevir clinical studies. Virology 2013; 444: 329-336 [PMID: 23876458 DOI: 10.1016/j.virol.2013.06.029]
117. Poveda E, Wyles DL, Mena A, Pedreira JD, Castro-Iglesias A, Cachay E. Update on hepatitis C virus resistance to direct-acting antiviral agents. Antiviral Res 2014; 108: 181-191 [PMID: 24911972 DOI: 10.1016/j.antiviral.2014.05.015]
118. Jacobson IM, Dore GJ, Foster GR, Fried MW, Radu M, Rafalsky VV, Moroz L, Craxi A, Peeters M, Lenz O, Ouwerkerk-Mahadevan S, De La Rosa G, Kalmeijer R, Scott J, Sinha R, Beumont-Mauviel M. Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet 2014; 384: 403-413 [PMID: 24907225 DOI: 10.1016/S0140-6736(14)60494-3]
119. Vidal LL, Santos AF, Soares MA. Worldwide distribution of the NS3 gene 80K polymorphism among circulating hepatitis C genotype 1 viruses: implication for simeprevir usage. J Antimicrob Chemother 2015; 70: 2024-2027 [PMID: 25835991 DOI: 10.1093/jac/dkv081]
120. Nakamoto S, Kanda T, Wu S, Shirasawa H, Yokosuka O. Hepatitis C virus NS5A inhibitors and drug resistance mutations. World J Gastroenterol 2014; 20: 2902-2912 [PMID: 24659881 DOI: 10.3748/wjg.v20.i11.2902]
121. McPhee F, Hernandez D, Yu F, Ueland J, Monikowski A, Carifa A, Falk P, Wang C, Fridell R, Eley T, Zhou N, Gardiner D. Resistance analysis of hepatitis C virus genotype 1 prior treatment null responders receiving daclatasvir and asunaprevir. Hepatology 2013; 58: 902-911 [PMID: 23504694 DOI: 10.1002/hep.26388]
122. Grebely J, Dore GJ. Can hepatitis C virus infection be eradicated in people who inject drugs? Antiviral Res 2014; 104: 62-72 [PMID: 24468275 DOI: 10.1016/j.antiviral.2014.01.002]
123. McGowan C, Harris M, Rhodes T. Hepatitis C avoidance in injection drug users: a typology of possible protective practices. PLoS One 2013; 8: e77038 [PMID: 24194855 DOI: 10.1371/journal.pone.0077038]
124. Reimer J, Schmidt CS, Schulte B, Gansefort D, Gölz J, Gerken G, Scherbaum N, Verthein U, Backmund M. Psychoeducation improves hepatitis C virus treatment during opioid substitution therapy: a controlled, prospective multicenter trial. Clin Infect Dis 2013; 57 Suppl 2: S97-104 [PMID: 23884073 DOI: 10.1093/cid/cit307]
125. Korthuis PT, Feaster DJ, Gomez ZL, Das M, Tross S, Wiest K, Douaihy A, Mandler RN, Sorensen JL, Colfax G, McCarty D, Cohen SE, Penn PE, Lape D, Metsch LR. Injection behaviors among injection drug users in treatment: the role of hepatitis C awareness. Addict Behav 2012; 37: 552-555 [PMID: 22209655 DOI: 10.1016/j.addbeh.2011.12.001]
126. Backmund M, Meyer K, Edlin BR. Infrequent reinfection after successful treatment for hepatitis C virus infection in injection drug users. Clin Infect Dis 2004; 39: 1540-1543 [PMID: 15546094 DOI: 10.1086/425361]
127. Grebely J, Knight E, Ngai T, Genoway KA, Raffa JD, Storms M, Gallagher L, Krajden M, Dore GJ, Duncan F, Conway B. Reinfection with hepatitis C virus following sustained virological response in injection drug users. J Gastroenterol Hepatol 2010; 25: 1281-1284 [PMID: 20594256 DOI: 10.1111/j.1440-1746.2010.06238.x]
128. Grebely J, Pham ST, Matthews G V, Petoumenos K, Bull RA, Yeung B, Rawlinson W, Kaldor J, Lloyd A, Hellard M, Dore GJ, White PA. Hepatitis C virus reinfection and superinfection among treated and untreated participants with recent infection. Hepatology 2012; 55: 1058-1069 [PMID: 22031335 DOI: 10.1002/hep.24754]
129. Hagan LM, Yang Z, Ehteshami M, Schinazi RF. All-oral, interferon-free treatment for chronic hepatitis C: cost-effectiveness analyses. J Viral Hepat 2013; 20: 847-857 [PMID: 24304454 DOI: 10.1111/jvh.12111]
130. Zanini B, Benini F, Pigozzi MG, Furba P, Giacò E, Cinquegrana A, Fasoli M, Lanzini A. Addicts with chronic hepatitis C: diffcult to reach, manage or treat? World J Gastroenterol 2013; 19: 8011-8019 [PMID: 24307794 DOI: 10.3748/wjg.v19.i44.8011.]
131. Tovo CV, de Mattos AA, de Almeida PR. Chronic hepatitis C genotype 1 virus: who should wait for treatment? World J Gastroenterol 2014; 20: 2867-2875 [PMID: 24659878 DOI: 10.3748/wjg.v20.i11.2867]
132. Calvo-Cidoncha E, González-Bueno J, Almeida-González CV, Morillo-Verdugo R. Influence of treatment complexity on adherence and incidence of blips in HIV/HCV coinfected patients. J Manag Care Spec Pharm 2015; 21: 153-157 [PMID: 25615004]
133. Razavi H, Waked I, Sarrazin C, Myers RP, Idilman R, Calinas F, Vogel W, Mendes Correa MC, Hézode C, Lázaro P, Akarca U, Aleman S, Balik I, Berg T, Bihl F, Bilodeau M, Blasco AJ, Brandão Mello CE, Bruggmann P, Buti M, Calleja JL, Cheinquer H, Christensen PB, Clausen M, Coelho HS, Cramp ME, Dore GJ, Doss W, Duberg AS, El-Sayed MH, Ergör G, Esmat G, Falconer K, Félix J, Ferraz ML, Ferreira PR, Frankova S, García-Samaniego J, Gerstoft J, Giria JA, Gonçales FL, Gower E, Gschwantler M, Guimarães Pessôa M, Hindman SJ, Hofer H, Husa P, Kåberg M, Kaita KD, Kautz A, Kaymakoglu S, Krajden M, Krarup H, Laleman W, Lavanchy D, Marinho RT, Marotta P, Mauss S, Moreno C, Murphy K, Negro F, Nemecek V, Örmeci N, Øvrehus AL, Parkes J, Pasini K, Peltekian KM, Ramji A, Reis N, Roberts SK, Rosenberg WM, Roudot-Thoraval F, Ryder SD, Sarmento-Castro R, Semela D, Sherman M, Shiha GE, Sievert W, Sperl J, Stärkel P, Stauber RE, Thompson AJ, Urbanek P, Van Damme P, van Thiel I, Van Vlierberghe H, Vandijck D, Wedemeyer H, Weis N, Wiegand J, Yosry A, Zekry A, Cornberg M, Müllhaupt B, Estes C. The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm. J Viral Hepat 2014; 21 Suppl 1: 34-59 [PMID: 24713005 DOI: 10.1111/jvh.12248]
134. Aspinall EJ, Corson S, Doyle JS, Grebely J, Hutchinson SJ, Dore GJ, Goldberg DJ, Hellard ME. Treatment of hepatitis C virus infection among people who are actively injecting drugs: a systematic review and meta-analysis. Clin Infect Dis 2013; 57 Suppl 2: S80-S89 [PMID: 23884071 DOI: 10.1093/cid/cit306]